Silvie Hojná, Hana Malínská, Martina Hüttl, Zdeňka Vaňourková, Irena Marková, Denisa Miklánková, Jaroslav Hrdlička, František Papoušek, Jan Neckář, Petr Kujal, Michal Behuliak, Hana Rauchová, Michaela Kadlecová, David Sedmera, Kristýna Neffeová, Eva Zábrodská, Veronika Olejníčková, Josef Zicha, Ivana Vaněčková
A combination of liver and heart dysfunction worsens the prognosis of human survival. The aim of this study was to investigate whether empagliflozin (a sodium-glucose transporter-2 inhibitor) has beneficial effects not only on cardiac and renal function but also on hepatic function. Adult (6-month-old) male spontaneously hypertensive rats (SHR) were fed a high-fat diet (60% fat) for four months to induce hepatic steatosis and mild heart failure. For the last two months, the rats were treated with empagliflozin (empa, 10 mg...
April 5, 2024: Biomedicine & Pharmacotherapy